All categories
42

The continuous popularity of the weight loss medicine market drives the demand for peptide raw materials

2023/10/17

Based on the company's prediction of the (GLP-1) market, we have plans to expand our production capacity. The company has started building new peptide production capacity at the beginning of this year, and please pay attention to the specific construction progress. On October 16th, the reporter called multiple companies involved in peptide raw material medicine business as investors, all of whom stated that they have planned or are currently expanding their production capacity for peptide raw material medicine business.

One of the driving factors behind this is the popularity of GLP-1 weight loss drugs. The industry generally believes that weight loss has both medical and consumer attributes, which is expected to drive the continuous growth of GLP-1 market demand, thereby driving the demand for upstream raw materials.

Data shows that GLP-1 is a peptide drug, and its upstream raw material is a peptide raw material drug. Industry insiders told reporters that peptide raw materials have always been a niche track and have not received high attention in the past. The emergence of weight loss indications for GLP-1 may change this.

On the news side, on October 11, Novo Nordisk announced the early termination of the Phase III clinical FLOW trial of smeglutide in the treatment of patients with type II diabetes and chronic kidney disease complicated with renal insufficiency, because it reached the preset efficacy criteria; On October 13th, Novo Nordisk raised its annual revenue forecast for the company. The company stated that due to higher expectations for weight loss drug sales, it is expected that the expected annual revenue growth will be increased from 27% -33% to 32% -38%, and the expected pre tax profit growth will be increased from 31% -37% to 40% -46%.

More potential indications and more optimistic sales expectations have once again boosted the expected demand for GLP-1 in the market, and upstream peptide raw materials are also actively preparing for production.

At the end of September, the leading pharmaceutical company in the industry announced that the newly constructed peptide production capacity is expected to be put into use in December 2023, and the production capacity will increase to 32000 liters by then; On October 13th, Hanyu Pharmaceutical disclosed a research summary that showed that the company's GLP-1 peptide raw material had been successfully sold to the United States and had entered a batch production and shipping state. In order to be busy with production and stocking, employees on the production line worked three shifts a day.

In addition, the patent period of major GLP-1 products such as Smeglutide and Liraglutide is about to expire or has already expired, which is expected to bring about a wave of research and development of peptide generic drugs, thereby further increasing the market demand for upstream raw materials.

On October 16th, the reporter called several peptide raw material pharmaceutical companies as investors. Some companies have stated that "the entire (GLP-1) market is very hot." Another company has stated that the peptide related API business is on the rise and is actively preparing for production. In the first half of this year, our GLP-1 API business grew rapidly, driving the growth of our peptide business. We have planned to expand our production capacity

Market investors have told reporters that in addition to GLP-1, the development of peptide conjugated drugs (PDCs) targeting peptides also has advantages in the fields of tumor treatment, nervous system, and other diseases, such as simple production processes and easier large-scale production.


JIN DUN CHEMICAL has built a special (meth) acrylic monomer manufacturing base in ZHEJIANG province. This makes sure the stable supply of   HEMAHPMAHEAHPAGMA with high level quality. Our special acrylate monomers are widely used for thermosetting acrylic resins, crosslinkable emulsion polymers, acrylate anaerobic adhesive, two-component acrylate adhesive, solvent acrylate adhesive, emulsion acrylate adhesive, paper finishing agent and painting acrylic resins in adhesive.We have also developed the new and special (meth) acrylic monomers and derivatives. Such as the fluorinated acrylate monomers, It can be widely used in coating leveling agent, paints, inks, photosensitive resins, optical materials, fiber treatment, modifier for plastic or rubber field. We are aiming to be the top supplier in the field of special acrylate monomers, to share our rich experience with better quality products and professional service.